Device Trial Radar · NCT07646938
MolecuLight All-in-One Oxygenation Clinical Utility
Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Mar 25, 2026
Primary completion
Mar 27, 2026
Study completion Mar 27, 2026
Sponsor
- Lead sponsor
- MolecuLight Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 15, 2026
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
This is a prospective, clinical evaluation of the MolecuLightDX+ with OxySight Module in wound care.
Conditions
- Wounds
Interventions
MolecuLightDX+ with OxySight ModuleDevice
MolecuLightDX+ with OxySight Module is an imaging device intended to acquire fluorescence, oxygenation, thermal, and measurement images of wounds.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Tissue oxygenation informing fluorescence-guided debridementTime frame: up to 1 month
- Tissue oxygenation changes before and after debridementTime frame: up to 1 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SerenaGroup Monroeville
Monroeville, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.